Clinical data | |
---|---|
Trade names | Cefzil, Cefproz, others |
Other names | Cefproxil |
AHFS/Drugs.com | Monograph |
MedlinePlus | a698022 |
License data | |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 95% |
Protein binding | 36% |
Elimination half-life | 1.3 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H19N3O5S |
Molar mass | 389.43 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cefprozil is a second-generation cephalosporin antibiotic.[1] Originally discovered in 1983, and approved in 1992,[2] it was sold under the tradename Cefzil by Bristol Meyers Squibb until 2010 when the brand name version was discontinued.[3] It continues to be available from various companies in its generic form.[4] It is used in the treatment of pharyngitis, tonsillitis, ear infections, acute sinusitis, bacterial exacerbation of chronic bronchitis, and skin and skin structure infections.[5] It is currently available as a tablet and as a liquid suspension.